Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - hydrocortisone; cinchocaine hydrochloride; aesculin; framycetin sulfate - ointment - 0.5%w/v+0.5%w/v+1%w/v+1%w/v percent weight/weight - corticosteroids; hydrocortisone

Ireland - English - HPRA (Health Products Regulatory Authority)

phoenix labs - hydrocortisone; cinchocaine hydrochloride; aesculin; framycetin sulphate - ointment - corticosteroids; hydrocortisone

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - hydrocortisone ; cinchocaine hydrochloride ; esculoside ; framycetin sulfate - suppositories - 5/5/10/10 milligram - hydrocortisone

Ireland - English - HPRA (Health Products Regulatory Authority)

opella healthcare france sas t/a sanofi - framycetin sulfate; aesculin; cinchocaine hydrochloride; hydrocortisone - ointment - 0.5%w/v+0.5%w/v+1%w/v+1%w/v percent weight/weight - corticosteroids; hydrocortisone

Canada - English - Health Canada

aptalis pharma canada ulc - dibucaine hydrochloride; esculin; framycetin sulfate; hydrocortisone - suppository - 5mg; 10mg; 10mg; 5mg - dibucaine hydrochloride 5mg; esculin 10mg; framycetin sulfate 10mg; hydrocortisone 5mg - anti-inflammatory agents

Canada - English - Health Canada

odan laboratories ltd - hydrocortisone; dibucaine hydrochloride; framycetin sulfate; esculin - suppository - 5mg; 5mg; 10mg; 10mg - hydrocortisone 5mg; dibucaine hydrochloride 5mg; framycetin sulfate 10mg; esculin 10mg - anti-inflammatory agents

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets, usp are indicated in the following conditions: 1.   endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3.   collagen diseases during an exacerbation or as maintenance therapy in selected cases of:

United States - English - NLM (National Library of Medicine)

greenstone llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets are indicated in the following conditions. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme (stevens-johnson syndrome) exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loeffler's syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired (autoimmune) hemolytic anemia erythroblastopenia (rbc anemia) congenital (erythroid) hypoplastic anemia for palliative management of: leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. to tide the patient over a critical period of the disease in: ulcerative colitis regional enteritis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement systemic fungal infections and known hypersensitivity to components

United States - English - NLM (National Library of Medicine)

par pharmaceutical - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets, usp are indicated in the following conditions. - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer - rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid ar

United States - English - NLM (National Library of Medicine)

lineage therapeutics inc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets are indicated in the following conditions. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic